exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease
Clinical Trial Grant
Administered By
Neurosurgery
Awarded By
BlueRock Therapeutics LP
Start Date
September 28, 2026
End Date
September 28, 2032
Administered By
Neurosurgery
Awarded By
BlueRock Therapeutics LP
Start Date
September 28, 2026
End Date
September 28, 2032